Treatment
Bevacizumab clinical trials
We’re tracking 422 recruiting studies that include Bevacizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT06543069RecruitingPhase 2
Combination therapy for unresectable peritoneal mesothelioma
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
BeijingAges 18 years+ - NCT07776691RecruitingPhase 3
Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05654454RecruitingPhase 3
Bevacizumab plus chemotherapy vs Avastin for advanced lung cancer
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
ArkhangelskAges 18 years+ - NCT06563986RecruitingPhase 2
Combination therapy for advanced colorectal cancer in the liver
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
UtrechtAges 18 years+ - NCT07775287RecruitingPhase 3
Petosemtamab plus chemotherapy for advanced colorectal cancer
This study tests a new drug called petosemtamab combined with chemotherapy for people with advanced colorectal cancer that has not responded to one prior treatment. The trial aims to see if adding petosemtamab helps the cancer shrink or grow more slowly compared to adding a standard targeted therapy like cetuximab or bevacizumab.
Los Angeles, CaliforniaAges 18 years+ - NCT06566755RecruitingPhase 3
New drug combo for a common type of colorectal cancer
This trial tests a combination of a new immunotherapy (cadonilimab) with standard chemotherapy (capecitabine, oxaliplatin) and bevacizumab for people with metastatic colorectal cancer that has a RAS mutation or is located on the right side of the colon. The goal is to see if this combination works better than the current standard of care as a first treatment.
Shenyang, LiaoningAges 18–75 - NCT07728019RecruitingPhase 2
New drug combo for untreated colon cancer with liver spread
This trial tests a new combination of drugs (Retlirafusp Alfa, Bevacizumab, and chemotherapy) with or without a short course of radiation for people with colorectal cancer that has spread only to the liver and who have not had any prior treatment. The goal is to see if this approach is safe and effective.
Wuhan, HubeiAges 18–75 - NCT06184698RecruitingPhase 2
Liposomal irinotecan, chemotherapy, and bevacizumab for advanced colorectal cancer
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Shijiazhuang, HebeiAges 18–75 - NCT07722494RecruitingPhase 3
Investigational drug plus bevacizumab for advanced colorectal cancer
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Wuhan, WuhanAges 18 years+ - NCT07722754RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of four drugs—bevacizumab, sintilimab, cetuximab, and irinotecan—in people whose colorectal cancer has spread and hasn't responded to previous treatments. The goal is to see if this new mix can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18–75 - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT07674732RecruitingPhase 2
Shorter radiation with immunotherapy for rectal cancer
This trial tests a shorter course of radiation followed by a combination of chemotherapy, immunotherapy, and a targeted drug (bevacizumab) for locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink the tumor enough for surgery while avoiding more extensive radiation.
Guangzhou, GuangdongAges 18–75 - NCT07653685RecruitingPhase 1/Phase 2
Study of a new drug with chemotherapy for advanced colorectal cancer
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07638852RecruitingPhase 2
Combining radiation and targeted drugs for triple-negative breast cancer brain tumors
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07642960Recruiting
Fine-needle Heat Treatment Plus Eye Injection for Corneal Blood Vessel Growth
This trial tests a combination of two treatments—a heat procedure and a medication injection—to reduce abnormal blood vessel growth on the clear front surface of your eye (cornea). The goal is to improve your vision and prevent further damage.
Ho Chi Minh City, Xuan HoaAges 18 years+ - NCT04973293Recruiting
Pre-surgery immunotherapy plus chemo and blood-vessel medicine for lung cancer
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06160206RecruitingPhase 2
Study of retifanlimab, bevacizumab, and radiation for recurrent glioblastoma
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
Scottsdale, ArizonaAges 18 years+ - NCT07623577RecruitingPhase 2
Sac-TMT and Bevacizumab for Triple-Negative Breast Cancer Brain Tumors
This trial tests a combination of two drugs (Sac-TMT and bevacizumab) to treat triple-negative breast cancer that has spread to the brain. Triple-negative means the cancer cells lack three common markers, making it harder to treat with standard therapies.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05640830RecruitingPhase 1/Phase 2
Trastuzumab, bevacizumab, and paclitaxel for HER2-positive stomach cancer
This trial tests a combination of anti-cancer medicines for HER2-positive advanced stomach cancer that has already been treated once. It may help shrink tumors and slow the disease by targeting HER2 and blocking tumor blood supply.
SeoulAges Any age - NCT07619235RecruitingPhase 4
Combination immunotherapy and chemotherapy for advanced bile duct cancer
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
Wuhan, HubeiAges 18–75 - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06609863Recruiting
Triple therapy for large liver cancer tumors
This trial tests combining a special type of chemo delivered directly to the liver (dTACE-HAIC) with two immunotherapy drugs (bevacizumab and atezolizumab) for people with huge liver cancer tumors (10 cm or larger). The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, None SelectedAges 18–75 - NCT06728865RecruitingPhase 2
Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Guangzhou, GuangdongAges 15–75
Common questions
- Are there clinical trials studying Bevacizumab?
- Yes. Clin2 currently lists 422 recruiting studies that include Bevacizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Bevacizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Bevacizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Bevacizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.